Terumo Of Japan To Try Pump In U.S. As Permanent Heart Replacement
This article was originally published in PharmAsia News
Executive Summary
Japan's Terumo plans to take its implanted heart device to the United States as early as next year to conduct clinical trials as a permanent heart replacement. The DuraHeart assist system for the left ventricle already has been tried in Europe as a permanent replacement, and patients have lived for more than three years with it as an alternative to waiting for a donor organ. After the U.S. trials, Terumo plans to bring the device home to Japan and seek approval. Until then, DuraHeart can be used only as a temporary implant to help the heart pump. (Click here for more - a subscription may be required
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.